Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.66 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.66 |
| ▸ | EEF2K | O00418 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25891578 | 0.91 | ALDH1A1 (0.67) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL426050 | 0.79 | MAPT (0.66) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL19000235 | 0.78 | MAPT (0.60) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL13186407 | 0.77 | ALDH1A1 (0.86) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL423967 | 0.77 | ADORA2A (0.62) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL14969506 | 0.76 | ALDH1A1 (0.97) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL430700 | 0.76 | MAPT (0.59) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL430861 | 0.76 | MAPT (0.59) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL13392956 | 0.76 | ALDH1A1 (0.84) | ALDH1A1KMT2ANPSR1MEN1MAPT | |
| SCHEMBL13186408 | 0.75 | KMT2A (0.86) | ALDH1A1KMT2ANPSR1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226027-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | UNIVERSITE TOULOUSE III - PAUL SABATIER (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230226027-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | UNIVERSITE TOULOUSE III - PAUL SABATIER (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230030517-A1 | EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) | 2023-02-02 | — | — | US | disclosed |
| WO-2021250231-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-12-16 | — | — | WO | disclosed |
| US-20210230179-A1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS EPAC INHIBITORS AND THEIR PHARMACEUTICAL USES | Universite Paris-Saclay (FR) | 2021-07-29 | — | — | US | disclosed |
| WO-2021116389-A1 | EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-06-17 | — | — | WO | disclosed |
| WO-2019234197-A1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS EPAC INHIBITORS AND THEIR PHARMACEUTICAL USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230179-A1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS EPAC INHIBITORS AND THEIR PHARMACEUTICAL USES | RAPGEF3, EPAS1, RAPGEF4 | ALDH1A1 3399/4885KMT2A 2904/4885NPSR1 1832/4885 |
| US-20230226027-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | TRPC1, SARS1, EPAS1 | ALDH1A1 2540/4885KMT2A 3095/4885NPSR1 3862/4885 |
| US-20230030517-A1 | EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | RAPGEF4, RAPGEF3, EPAS1 | ALDH1A1 2056/4885KMT2A 2721/4885NPSR1 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.